Dr. Tony Reid currently serves as executive director, clinical trials of the Rebecca and John Moores Cancer Center at the University of California at San Diego (UCSD). He is currently a professor of medicine with primary specialty in cancer, gastrointestinal cancers, pancreatic cancer and hematology/blood diseases at UCSD. Dr. Reid has published broadly on the use of a new agent for the treatment of these malignancies and conducts a variety of clinical trials that utilize correlative studies to translate between important clinical and basic science observations. He has focused most of his work on early phase therapeutic clinical trials using gene therapy strategies to enhance the immune response to these malignancies. He was also the lead investigator on the original trials using Onyx-015 to treat colorectal cancer and has pioneered the use of adenoviral and vaccinia vectors for the treatment of cancer. Dr. Reid has been at the forefront of using interventional radiology to selectively deliver therapeutic directly to the tumor using the tumor's own vascular supply.
Dr. Reid has received national recognition for his work, including awards from the Interferon Society, the International Society of Gene Therapy and the Society for Interventional Radiology. He is on the review board of numerous prestigious journals including Nature Cancer Gene Therapy, Gene Therapyand Clinical Cancer Research.
Dr. Reid completed his residency and fellowship at Stanford University, where he also received his M.D. and a Ph.D. in biochemistry.